Amgen Stock Surges 3.5% as Healthcare Hits Record High

Earnings
โดย GuruFocus·US·Read original
Summary · why it matters

Amgen shares surged roughly 3.5% to $440.08 Wednesday morning as healthcare stocks ripped to a record high, powered by fresh excitement around Merck and Moderna's melanoma breakthrough and a market rotation away from battered semiconductor names. The biotech heavyweight behind Repatha, Enbrel and MariTide reported second-quarter revenue up 10% to $10.1 billion, product sales up 9%, and GAAP earnings up 65% to $4.37 per share. Twenty-two medicines delivered double-digit sales growth, seventeen products are running above $1 billion in annualized sales, and six key growth products surged 26% to generate nearly 70% of product revenue. The stock now trades at a roughly 19% premium to its $365.04 GF Value, putting pressure on execution amid Prolia declines and Tavneos uncertainty, but investors are looking past those cracks to accelerating earnings, multiple blockbuster franchises, defensive healthcare demand, and MariTide's potential in obesity.

Impact on stocks 4

Biotech & Genomic Medicine▲ · 3 stocks
Amgen Inc
AMGN
▲ PositiveCapitalrelevance

Q2 revenue up 10%, product sales up 9%, GAAP EPS up 65% to $4.37, with accelerating earnings and multiple blockbuster franchises.

Merck & Company Inc
MRK
▲ PositiveTechnologyrelevance

Merck's melanoma breakthrough with Moderna is a key driver of the healthcare rally, boosting sentiment.

Moderna Inc
MRNA
▲ PositiveTechnologyrelevance

Moderna's melanoma breakthrough with Merck is a key driver of the healthcare rally, boosting sentiment.

Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketDXNews